Skip to content

AI-Powered Forecasts for Biotech Investors

Home
Tools
About
Join ScanScor
Log In
- Panel

ScanScor

The AI Biotech Breakout Prediction Strategy

ScanScor

The AI Biotech Breakout Prediction Strategy

Predictions
Scores
News Stream

prostate cancer

AI Biomed Predictions

CADL – Promising Phase 3 Data Could Propel Candel Therapeutics

ScanScor Admin / March 18, 2026

Search

Tools

Predictions
Scores
News Stream

Recent Comments

Recent Comments

4 days ago NBY – Investor Alert: NovaB... – 🌈🚀 NBY: From Biotech Underdog to Absolute Moonshot 🚀🌈... by ScanScor Admin
1 week ago SNGX – Soligenix Set for Br... – ScanScor Update: SNGX is in the final three weeks of it... by ScanScor Admin
2 weeks ago INM – InMed Set for Breakou... – No prediction right now. Because the only visible “near-... by ScanScor Admin
2 weeks ago LXRX – Lexicon Gears Up for... – 🚀 Lexicon Pharmaceuticals (LXRX) Prediction UpdateMulti-... by ScanScor Admin
2 weeks ago XBIT – XBiotech Poised for ... – XBIT — Catalyst No Longer Valid Key reasons ⚠️ Rheumato... by ScanScor Admin

Recent Posts

CADL – Promising Phase 3 Data Could Propel Candel Therapeutics
ACOG – Alpha Cognition Set for Growth with Upcoming BEACON Study Results
CLRB – Cellectar Poised for Breakout with Key EMA Filing
ALXO – ALX Oncology Set for Breakout with Key 2026 Trial Results
LXRX – Lexicon Gears Up for Breakout with Key FDA Approvals Ahead

ScanScor empowers traders and investors with instant
AI-driven access to trusted intelligence.

🧠 Powered by real-time AI
🔍 Trained to find the moment before it moves

Terms and Conditions
About
Join the ScanScor Revolution

Disclaimer: ScanScor provides research and educational information only. Nothing on this site is financial advice or a recommendation to buy or sell securities. ScanScor does not provide forecasts or guarantee any outcomes. Past performance is not indicative of future results.

Copyright © 2026 ScanScor

Best viewed on desktop. Mobile optimization coming soon.

Scroll to Top